Program Description
Management of non-small cell lung cancer has significantly evolved with the expanding role of molecular testing to guide treatment decisions. Testing for molecular and immune biomarkers allows for targeted disease management. This discussion focuses on the lesser-known biomarkers RET, MET, and KRAS and their corresponding targeted therapies. Patient education points regarding adherence and adverse effect management will also be reviewed.
Target audience: Health-system and oncology pharmacists
Type of activity: Knowledge
Release date: July 29, 2022
Expiration date: July 29, 2023
Time to complete activity: 0.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non−small cell lung cancer
- Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic non−small cell lung cancer expressing RET, MET, and KRAS mutations
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
